scholarly journals Factors associated with HIV stigma and the impact of a nonrandomized multi-component video aimed at reducing HIV stigma among a high-risk population in New York City

AIDS Care ◽  
2015 ◽  
Vol 27 (6) ◽  
pp. 772-776 ◽  
Author(s):  
Alexis V. Rivera ◽  
Jennifer DeCuir ◽  
Natalie D. Crawford ◽  
Silvia Amesty ◽  
Katherine Harripersaud ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
High Risk ◽  
York City ◽  
Hiv Stigma ◽  
High Risk Population ◽  
Risk Population ◽  
Factors Associated ◽  
The Impact

Drug Tests and the Prediction of Pretrial Misconduct: Findings and Policy Issues

1992 ◽  
Vol 38 (4) ◽  
pp. 557-582 ◽  
Author(s):  
Steven Belenko ◽  
Iona Mara-Drita ◽  
Jerome E. McElroy
Keyword(s):  
New York ◽  
New York City ◽  
Drug Abuse ◽  
High Risk ◽  
York City ◽  
Drug Testing ◽  
Predictive Utility ◽  
Policy Issues ◽  
Urine Screening ◽  
The Impact

Growing concern about the impact of drug abuse and the proliferation of drug-related caseloads in urban courts has fueled interest in urine screening and monitoring programs to detect drug use among pretrial defendants. Research on the predictive utility of urine tests in New York City and elsewhere suggests that this information does not improve the ability to classify high-risk offenders, nor does urine monitoring appear to reduce pretrial misconduct under supervised release programs. Coupled with technical and process concerns surrounding drug tests, the evidence thus far suggests caution in the adoption of pretrial drug-testing programs.

scholarly journals Factors Associated with Recent HIV Testing among Heterosexuals at High Risk for HIV Infection in New York City

2016 ◽  
Vol 4 ◽  
Author(s):  
Marya Gwadz ◽  
Charles M. Cleland ◽  
Alexandra Kutnick ◽  
Noelle R. Leonard ◽  
Amanda S. Ritchie ◽  
...  
Keyword(s):  
New York ◽  
New York City ◽  
High Risk ◽  
Hiv Infection ◽  
Hiv Testing ◽  
York City ◽  
Factors Associated

Prevalence and Factors Associated With Sex Trading Among High-Risk Substance-Involved Women Under Community Supervision in New York City

2019 ◽  
Vol 47 (5) ◽  
pp. 529-546
Author(s):  
Tina Jiwatram-Negrón ◽  
Stacey Shaw ◽  
Xin Ma ◽  
Nabila El-Bassel ◽  
Louisa Gilbert
Keyword(s):  
New York ◽  
New York City ◽  
High Risk ◽  
York City ◽  
Crack Cocaine ◽  
Community Supervision ◽  
Minority Status ◽  
Multivariate Logistic Regression ◽  
Sex Trading ◽  
Factors Associated

This article examines the prevalence of and factors associated with sex trading among a high-risk sample of 337 substance-involved women in community corrections enrolled in an HIV risk reduction study in New York City, using baseline data. Forty percent of the sample reported trading sex for money, food, drugs, or other resources in the prior 90 days. Multivariate logistic regression analyses showed significant associations among age, ethnic minority status, marital status, prior mental health hospitalization, binge drinking, and having recently been in jail/prison and sex trading ( p < .05). Women who reported that both they and their partner recently (past 90 days) used crack/cocaine or that their partner recently used crack/cocaine were more likely to report sex trading than women who reported that neither they nor their partner recently used crack/cocaine ( p < .05). Study findings underscore an urgent need for multipronged intervention efforts that simultaneously address multilevel risk exposures.

scholarly journals Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Maitri Kalra ◽  
Yan Tong ◽  
David R. Jones ◽  
Tom Walsh ◽  
Michael A. Danso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Neoadjuvant Therapy ◽  
Triple Negative ◽  
Residual Disease ◽  
Disease Free Survival ◽  
Parp Inhibition ◽  
High Risk Population ◽  
Risk Population ◽  
The Impact

AbstractPatients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population. Patients with TNBC or deleterious BRCA mutation (TNBC/BRCAmut) who had >2 cm of invasive disease in the breast or persistent lymph node (LN) involvement after neoadjuvant therapy were assigned 1:1 to cisplatin alone or with rucaparib. Germline mutations were identified with BROCA analysis. The primary endpoint was 2-year disease-free survival (DFS) with 80% power to detect an HR 0.5. From Feb 2010 to May 2013, 128 patients were enrolled. Median tumor size at surgery was 1.9 cm (0–11.5 cm) with 1 (0–38) involved LN; median Residual Cancer Burden (RCB) score was 2.6. Six patients had known deleterious BRCA1 or BRCA2 mutations at study entry, but BROCA identified deleterious mutations in 22% of patients with available samples. Toxicity was similar in both arms. Despite frequent dose reductions (21% of patients) and delays (43.8% of patients), 73% of patients completed planned cisplatin. Rucaparib exposure was limited with median concentration 275 (82–4694) ng/mL post-infusion on day 3. The addition of rucaparib to cisplatin did not increase 2-year DFS (54.2% cisplatin vs. 64.1% cisplatin + rucaparib; P = 0.29). In the high-risk post preoperative TNBC/BRCAmut setting, the addition of low-dose rucaparib did not improve 2-year DFS or increase the toxicity of cisplatin. Genetic testing was underutilized in this high-risk population.

Sign in / Sign up

Export Citation Format

Share Document